Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cancertestis antigen HCA587 protein vaccine and application thereof

A technology of protein vaccine and testicular antigen, which is applied in the field of medical oncology, can solve the problems of tumor growth rate and survival period of tumor-bearing mice that have not seen the anti-tumor effect of epitope peptide vaccine, so as to inhibit the growth rate, prolong the survival period, and achieve good results. The effect of anti-tumor effect

Inactive Publication Date: 2011-09-14
PEKING UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous research work mainly focused on the identification of MHC class I molecular epitopes of HCA587 protein. Although epitope peptide vaccines can induce cellular immune responses in vivo, no anti-inflammatory effects of epitope peptide vaccines have been found in animal experiments with tumor-bearing mice. Tumor effect (expressed in no effect on tumor growth rate and survival period of tumor-bearing mice)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancertestis antigen HCA587 protein vaccine and application thereof
  • Cancertestis antigen HCA587 protein vaccine and application thereof
  • Cancertestis antigen HCA587 protein vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Expression and purification of embodiment 1HCA587 recombinant protein

[0042] The cDNA encoding HCA587 (AF239802) was ligated to the pGEX-6p-1 vector through restriction sites BamHI and Sal I, transformed into Escherichia coli BL21(DE3), induced expression with 0.2mM IPTG at 25°C for 5 hours, and centrifuged at 4000rpm at 4°C for 15 minutes , collect the bacteria, dissolve in the lysate (pH 7.4PBS, 1mM EDTA and 1mM DTT), sonicate 10 times, each lasting 15 seconds, centrifuge at 14,000rpm for 15 minutes, and discard the precipitate.

[0043] The fusion protein was firstly subjected to affinity chromatography on a GST Sepharose 4B (GE) column, washed and dissolved in lysis buffer (20mM Tris, 150mM NaCl, 1mM DTT, 1mM EDTA, pH7.4), and PPase (250ug / 1ml resin ) at 4°C for 3 hours to remove GST. The collected protein was passed through HiTrap Q HP (GE) column, the buffer solution was 20mM Hepes, 1M NaCl, pH6.7, and the flow rate was 5ml / min. The collected fractions were th...

Embodiment 2

[0045] Preparation and immunization procedure of embodiment 2HCA587 protein vaccine

[0046] Option One

[0047] Mix and emulsify 50 μl (10 μg) of HCA587 protein and 50 μl (12 μg) of CpG to make a protein vaccine.

[0048] Take 6-8 week-old mice (C57BL / 6), 3 mice in each group, and inject 100 μl of the above-mentioned protein vaccine into each mouse, subcutaneously inject at the base of the tail for the first immunization, and 20 days later, inject again for the second immunization.

[0049] Option II

[0050] Mix and emulsify 50 μl (10 μg) of HCA587 protein and 50 μl (12 μg) of ISCOM to make a protein vaccine.

[0051] Take 6-8 week-old mice (C57BL / 6), 3 mice in each group, and inject 100 μl of the above-mentioned protein vaccine into each mouse, subcutaneously inject at the base of the tail for the first immunization, and 20 days later, inject again for the second immunization.

[0052] third solution

[0053] Mix and emulsify 50 μl (10 μg) of HCA587 protein, 25 μl (12 μ...

Embodiment 3

[0060] Example 3 Enzyme-linked immunospot (ELISpot) method to measure the cell frequency of secreting IFN-γ in mouse splenocytes

[0061] (1) 96-well flat-bottomed nitrocellulose plates were coated with anti-mouse IFN-γ monoclonal antibody (5 μg / ml in pH 9.6 carbonate buffer), and left overnight at 4°C;

[0062] (2) After washing with 0.05% Tween PBS (PBST) the next day, the plate was sealed with 1640 culture solution containing 10% FCS in a 37°C incubator for 2 hours;

[0063] (3) After washing with PBST, for the immunized mice described in Example 2, add 5×10 5 Splenocytes, then add 2.5μg / ml HCA587 protein, the control group includes media control and OVA irrelevant protein control, each triplicate hole, at 37 ° C, 5% CO 2 Incubate for 20 hours;

[0064] (4) Wash the plate 3 times with PBST to remove residual cells; then add biotin-labeled anti-mouse IFN-mAb (1.5 μg / ml), incubate at 37°C for 2 hours, and wash the plate 6 times;

[0065] (5) Add alkaline phosphatase-labele...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a Cancertestis antigen HCA587 protein vaccine and application thereof. The protein vaccine comprises HCA587 protein, complete Freud's adjuvant, incomplete Freud's adjuvant, ISCOM (immunostimulating complex) and CpG ODN-1826. The HCA587 protein vaccine can induce CD4 and CD8T cell immune response and humoral immune response, can prevent the growth of mouse tumors, can prolong the survival time of mice with tumor, can inhibit the growth speed of the tumors and has a good antitumor effect. The invention lays the scientific function for the clinical application of the HCA587 protein vaccine.

Description

technical field [0001] The invention belongs to the technical field of medical oncology, and in particular relates to a tumor-testis antigen HCA587 protein vaccine and its application. Background technique [0002] The morbidity and mortality of tumors are increasing year by year. At present, cancer has become the number one killer that seriously threatens human health. Despite the continuous progress in surgical treatment, chemotherapy and radiotherapy of tumors, a considerable proportion of patients still die. In recent years, with the continuous revelation of the molecular and immune mechanisms of tumors, tumor-specific immunotherapy has received increasing attention. [0003] The identification of tumor-specific antigens is a prerequisite for the development of effective tumor immunotherapy pathways. Tumor-testis antigen (abbreviated as CT antigen) is a major tumor-specific antigen, which is mainly expressed in normal testis tissue and different types of tumor tissue. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00
Inventor 张毓尹艳慧陈娟娟
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com